BioELife Corp.

LITHOTCHealthcare● Active

$0.00

+$0.00(+0.00%)

Market Cap$941

P/E Ratio—

52W High$0.0002

52W Low$0.000001

Avg Volume7

Open$0.00

Beta1.50

Free Cash Flow Financials Revenue

BioELife Corp. (LITH) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

LITH · free cash flow · updated Jun 8, 2026

Core FCF metrics

LITH · FCF · TTM · margin & CAGR

Free cash flow was −$76,691 for FY2018 (fiscal year ending 2018-12-31), up 37.2% year-over-year

FY2018 Free Cash Flow−$76,691▲ +37.2% YoY

Trailing 12M (TTM)−$188,101trailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

LITH · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2018Latest−$76,071(0M)−$76,691▲ +37.2%—

FY2017−$122,050(0M)−$122,050▲ +8.8%—

FY2016−$129,404(0M)−$133,849▼ 301.1%—

FY2015−$33,367(0M)−$33,367▲ +9.3%—

FY2014−$36,783(0M)−$36,783▲ +37.9%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

LITH · P/FCF · FCF yield · FCF per share

BioELife Corp. (LITH) reported negative free cash flow of −$0.00B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2018 · 2018-12-31

Cash flow statement summary

LITH · cash flow statement · operating / investing / financing

For FY2018, BioELife Corp. generated −$0.1M in operating cash flow and spent 0M in capital expenditures, yielding −$0.1M in free cash flow.

Operating Activities

−$0.1M

Cash from core business operations

2018-12-31

Investing Activities

+$0.1M

CapEx, acquisitions & investments

2018-12-31

Financing Activities

+$0.0M

Buybacks, dividends & debt

2018-12-31

FCF FormulaOperating CF (−$0.1M) − |CapEx| (0M) = FCF (−$0.1M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

LITH vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

BioELife Corp.YOU

LITH

−$76,691+37.2%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

BioELife Corp. (LITH) reported free cash flow of −$76,691 for FY2018 (fiscal year ending 2018-12-31), up 37.2% year-over-year.

BioELife Corp. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 12 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

LITH free cash flow · 8 questions

BioELife Corp. free cash flow was −$76,691 for FY2018, up 37.2% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$188,101.

LITH free cash flowLITH FCFLITH FCF 2018LITH free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · BioELife Corp. · BioELife Corp. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026